Arcutis Biotherapeutics Inc

Arcutis insider selling is a planned, rule‑based strategy—investors should focus on the company’s positive biotech pipeline and market sentiment to gauge future upside.

Arcutis insider selling: Patrick’s tax‑plan sale is routine, not a red flag, amid strong market momentum and ZORYVE gains.

Arcutis Biotherapeutics insider sale: CMO Burnett Patrick sells 2,490 shares under a 10b‑5‑1 plan, hinting at short‑term liquidity amid volatile stock and uncertain earnings.